D-Index & Metrics Best Publications
Genetics and Molecular Biology
Japan
2022

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Genetics and Molecular Biology D-index 132 Citations 80,979 492 World Ranking 115 National Ranking 5

Research.com Recognitions

Awards & Achievements

2022 - Research.com Genetics and Molecular Biology in Japan Leader Award

2019 - Distinguished Fellows of the American Association of Immunologists (AAI)

2018 - Nobel Prize for their discovery of cancer therapy by inhibition of negative immune regulation

2012 - Robert Koch Prize

2001 - Member of the National Academy of Sciences

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • DNA
  • Enzyme

Tasuku Honjo focuses on Molecular biology, Immunology, Cell biology, Genetics and T cell. His Molecular biology research is multidisciplinary, incorporating perspectives in Immunoglobulin class switching, Antibody, Cytidine deaminase, Antigen and Complementary DNA. His study in Immunoglobulin class switching is interdisciplinary in nature, drawing from both Somatic hypermutation, Immunoglobulin A and Lymphoma.

As a member of one scientific family, Tasuku Honjo mostly works in the field of Immunology, focusing on Receptor and, on occasion, Peripheral tolerance and Inhibitory postsynaptic potential. His research in Cell biology intersects with topics in Embryonic stem cell and CD40. His research integrates issues of T lymphocyte, CD8 and B cell in his study of T cell.

His most cited work include:

  • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. (3499 citations)
  • Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme (2778 citations)
  • PD-L2 is a second ligand for PD-1 and inhibits T cell activation (2108 citations)

What are the main themes of his work throughout his whole career to date?

Tasuku Honjo spends much of his time researching Molecular biology, Genetics, Gene, Immunology and Antibody. His Molecular biology study combines topics from a wide range of disciplines, such as Nucleic acid sequence, DNA, Immunoglobulin heavy chain, Immunoglobulin class switching and Complementary DNA. His Immunoglobulin class switching research incorporates themes from Somatic hypermutation and Cytidine deaminase.

Exon and Southern blot are among the areas of Gene where Tasuku Honjo concentrates his study. As a part of the same scientific family, he mostly works in the field of Immunology, focusing on Cell biology and, on occasion, T cell. His T cell research is multidisciplinary, incorporating elements of Cytotoxic T cell, Receptor and Cell culture.

He most often published in these fields:

  • Molecular biology (47.01%)
  • Genetics (23.25%)
  • Gene (22.34%)

What were the highlights of his more recent work (between 2007-2021)?

  • Cytidine deaminase (10.52%)
  • Immunology (18.70%)
  • Molecular biology (47.01%)

In recent papers he was focusing on the following fields of study:

Tasuku Honjo mainly investigates Cytidine deaminase, Immunology, Molecular biology, Somatic hypermutation and Activation-induced deaminase. His work deals with themes such as Uracil-DNA glycosylase, Carcinogenesis and Homologous recombination, which intersect with Cytidine deaminase. His studies deal with areas such as Notch signaling pathway, Cellular differentiation, Gene, Gene knockdown and Antibody as well as Molecular biology.

Tasuku Honjo has researched Somatic hypermutation in several fields, including Mutant and Immunoglobulin class switching. He combines subjects such as Mutation, Immunoglobulin gene and RNA, RNA editing with his study of Activation-induced deaminase. His T cell research is multidisciplinary, relying on both Cytotoxic T cell, FOXP3 and Cell biology.

Between 2007 and 2021, his most popular works were:

  • Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer (579 citations)
  • A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. (553 citations)
  • Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma† (499 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • DNA
  • Enzyme

His main research concerns Immunology, Cytidine deaminase, Molecular biology, Immune system and Activation-induced deaminase. His biological study spans a wide range of topics, including Carcinogenesis, Chromatin and Somatic hypermutation. His work carried out in the field of Molecular biology brings together such families of science as Progenitor cell, Stem cell, HES1, Notch signaling pathway and DNA-binding protein.

The concepts of his Immune system study are interwoven with issues in Receptor and Cell biology. The Activation-induced deaminase study combines topics in areas such as Immunoglobulin gene, Transcription factor, Gene, Transcriptional regulation and Hepatitis B virus. His T cell research incorporates elements of Cytotoxic T cell and Cytokine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme

Masamichi Muramatsu;Kazuo Kinoshita;Sidonia Fagarasan;Shuichi Yamada.
Cell (2000)

4777 Citations

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Gordon J. Freeman;Andrew J. Long;Yoshiko Iwai;Karen Bourque.
Journal of Experimental Medicine (2000)

4627 Citations

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Yasumasa Ishida;Yasutoshi Agata;Keiichi Shibahara;Tasuku Honjo.
The EMBO Journal (1992)

3201 Citations

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

Hiroyuki Nishimura;Masato Nose;Hiroshi Hiai;Nagahiro Minato.
Immunity (1999)

3078 Citations

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary.
Nature Immunology (2001)

2801 Citations

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Yoshiko Iwai;Masayoshi Ishida;Yoshimasa Tanaka;Taku Okazaki.
Proceedings of the National Academy of Sciences of the United States of America (2002)

2553 Citations

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Yasutoshi Agata;Akemi Kawasaki;Hiroyuki Nishimura;Yasumasa Ishida.
International Immunology (1996)

1777 Citations

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Hiroyuki Nishimura;Taku Okazaki;Yoshimasa Tanaka;Kazuki Nakatani.
Science (2001)

1755 Citations

Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).

Patrick Revy;Taro Muto;Yves Levy;Frédéric Geissmann.
Cell (2000)

1714 Citations

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.

Junzo Hamanishi;Masaki Mandai;Masashi Iwasaki;Taku Okazaki.
Proceedings of the National Academy of Sciences of the United States of America (2007)

1457 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Tasuku Honjo

Gordon J. Freeman

Gordon J. Freeman

Harvard University

Publications: 163

Frederick W. Alt

Frederick W. Alt

Boston Children's Hospital

Publications: 161

Hideo Yagita

Hideo Yagita

Juntendo University

Publications: 148

Lieping Chen

Lieping Chen

Yale University

Publications: 138

Michel C. Nussenzweig

Michel C. Nussenzweig

Rockefeller University

Publications: 127

Arlene H. Sharpe

Arlene H. Sharpe

Harvard University

Publications: 126

Hiroshi Kiyono

Hiroshi Kiyono

University of Tokyo

Publications: 124

Miyuki Azuma

Miyuki Azuma

Tokyo Medical and Dental University

Publications: 82

Raphael Kopan

Raphael Kopan

Cincinnati Children's Hospital Medical Center

Publications: 79

Freddy Radtke

Freddy Radtke

École Polytechnique Fédérale de Lausanne

Publications: 78

Ryoichiro Kageyama

Ryoichiro Kageyama

Kyoto University

Publications: 78

Kiyoshi Takatsu

Kiyoshi Takatsu

University of Toyama

Publications: 77

Paolo Casali

Paolo Casali

The University of Texas Health Science Center at San Antonio

Publications: 75

Junji Yodoi

Junji Yodoi

Kyoto University

Publications: 73

Andrea Cerutti

Andrea Cerutti

Icahn School of Medicine at Mount Sinai

Publications: 70

Klaus Rajewsky

Klaus Rajewsky

Max Delbrück Center for Molecular Medicine

Publications: 70

Something went wrong. Please try again later.